Molecular genetics of urothelial malignancies: Mismatch repair genes as markers for detection and prognosis?

Urologic Oncology

Volumn 6, Issue 5, 2001, Pages 211-219

  Leach, Fredrick S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer detection; Mismatch repair; Prognosis; Urothelial malignancy

Indexed keywords

CISPLATIN; DOXORUBICIN; MARKER;

ADJUVANT THERAPY; BASE MISPAIRING; CANCER DIAGNOSIS; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; CYSTOSCOPY; CYTOLOGY; DNA REPAIR; ENDOSCOPIC THERAPY; FEMALE; GENE; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; MALE; METASTASIS; MOLECULAR GENETICS; PRIORITY JOURNAL; PROGNOSIS; TUMOR RECURRENCE; UNITED STATES; UROGENITAL TRACT TUMOR;

EID: 0034888760     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(01)00144-2     Document Type: Conference Paper

References (65)

1. Cancer statistics, 2000
2. Prognostic markers in bladder cancer; a contemporary review of the literature
3. A genetic model for colorectal tumorigenesis
4. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53
5. Accumulation of nuclear p53 and tumor progression in bladder cancer
6. Altered expression of the retinoblastoma gene product; prognostic indicator in bladder cancer
7. Frequent association of p53 gene mutation in invasive bladder cancer
8. JC, Reuter VE, Galan T, Fair WR, Cordon-Cardo C. Molecular genetic alterations in superficial and locally advanced human bladder cancer
9. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder
10. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers
11. Significance of cyclin D1 overexpression in transitional cell carcinoma of the urinary bladder and its correlation with histopathologic features
12. C-erbB-2 gene amplification; a molecular marker in recurrent bladder tumors?
13. Heterogeneity of erbB-2 gene amplification in bladder cancer
14. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder
15. Eukaryotic DNA mismatch repair
16. Mammalian DNA mismatch repair
17. Mismatch repair in replication fidelity, genetic recombination, and cancer biology
18. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer
19. hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds
20. Mutations of a mutL homolog in hereditary colon cancer
21. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer
22. Mutations of a mutS homolog in hereditary nonpolyposis colon cancer
23. The human mutator gene MSH2 and its association with hereditary nonpolyposis colon cancer
24. Molecular basis of HNPCC; Mutations of MMR genes
25. Extracolonic cancer in hereditary nonpolyposis colorectal cancer
26. Genetics, natural history, tumor spectrum and pathology of hereditary nonpolyposis colorectal cancer; an updated review
27. The Lynch syndrome II and urologic malignancies
28. Expression of the human mismatch repair gene hMSH2; a potential marker for urothelial malignancy
29. Human mismatch repair gene (hMSH2) product expression in relation to recurrence of transitional cell carcinoma of the urinary bladder
30. Mechanisms and biological effects of mismatch repair
31. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
32. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
33. Binding of mismatched microsatellite DNA sequences by the human MSH2 protein
34. MLH1, PMS1 and MSH2 interactions during the initiation of DNA mismatch repair in yeast
35. ATP-dependent interaction of human mismatch repair proteins and dual role of PCNA in mismatch repair
36. Requirement for PCNA in DNA mismatch repair at a step preceding DNA resynthesis
37. Cloning and expression analysis of a meiosis-specific MutS homolog; the human MSH4 gene
38. Cloning, structural characterization, and chromosomal localization of the human orthologue of Saccharomyces cerevisae MSH5 gene
39. Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair
40. Clues to the pathogenesis of familial colorectal cancer
41. Microsatellite instability in cancer of the proximal colon
42. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis
43. Hypermutability and mismatch repair deficiency in RER+ tumor cells
44. Germline msh6 mutations in colorectal cancer families
45. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes
46. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability
47. Somatic mutations in the hMSH2 gene in microsatellite unstable colorectal carcinomas
48. Microsatellite instability in bladder cancer
49. Expression of the mismatch repair gene hMSH2 in normal and neoplastic tissues
50. The human mismatch repair gene hMSH2 is mutated in the prostate cell line LNCaP
51. Microsatellite instability, mismatch repair deficiency and genetic defects in human cancer cell lines
52. Allelic loss and microsatellite instability in prostate cancer in japan
53. High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma
54. Genomic instability of microsatellite repeats in prostate cancer; relationship to clinicopathological variables
55. Expression of human mutS homolog 2 (hMSH2) protein in resting and proliferating cells
56. Differential cellular expression of the human MSH2 repair enzyme in small and large intestine
57. Molecular detection of primary bladder cancer by microsatellite analysis
58. Involvement of the DNA mismatch repair system in antineoplastic drug resistance
59. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint
60. Role of BAX in the apoptotic response to anticancer agents
61. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine
62. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin
63. Mismatch repair and differential sensitivity of mouse and human cells to methylating agents
64. Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation
65. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer